disease than the earlier infection. Such new variants can be logically expected to be resistant to antibodies as well 
as vaccines. Additionally, it has already been found or suspected that many of the new variants are or are expected to 
be resistant to existing antibody drugs. Given the known weak effectiveness of available antibody drugs, even a small 
resistance would likely allow a variant to escape the current antibody drugs. 
Of note, the currently approved drugs, namely remdesivir, the Regeneron antibody cocktail, or the Eli Lilly single 
antibody drug, had demonstrated only moderate effectiveness in clinical trials. Remdesivir reduced the length to 
recovery in severe disease cases in hospitalized patients by approximately six days, from 18 days to 12 days in a 
clinical trial, NIAID ACIT-1, reported in its European (CHMP) Product Information. The Regeneron drug dosing in a 
clinical trial was at 2.4g or 8g of total antibody, while the Eli Lilly antibody drug dose in the combination therapy 
clinical trial was at 5.6g, although single antibody therapy dosages from 700mg upwards are also being evaluated. These 
high dosage levels are indicative of relatively weak effectiveness. The U.S. Food and Drug Administration (FDA) has 
granted Emergency Use Authorization (EUA) for the Regeneron REGN-COV-2 cocktail, and also to a Eli Lilly single 
antibody bamlanivimab (LY-CoV555) with both authorizations restricted to the treatment of mild to moderate COVID-19 
only. Thus, further loss of effectiveness of the existing drugs as new variants emerge would have devastating 
consequences. 
Vaccines, it is now clearly apparent, are neither the great hope nor panacea that the scientific community had once 
thought for this pandemic. The South African variant, 501Y.v2 is of great concern as scientists believe it may escape 
current vaccines. Its mutations are also shared by the Brazilian variant, P.1. Vaccinated persons coming down with 
SARS-CoV-2 infection has already been witnessed. As more variants emerge, existing vaccines would very likely lose 
effectiveness. An additional concern is that some of the variants are expected to result in greater total fatality 
numbers. A more contagious variant would cause more number of cases and thus greater number of fatalities. A more 
lethal variant would lead to a greater proportion of infected patients dying (i.e. a greater case fatality rate). The 
UK B.1.1.7 variant is currently estimated by the UK scientific advisory body, namely New and Emerging Respiratory Virus 
Threats Advisory Group (NERVTAG), to be highly contagious (transmissible), infectious, and more lethal than previous 
variants. 
The SARS-CoV-2 virus, despite its current and future variants, is extremely unlikely to escape a broad-spectrum 
anti-coronavirus drug like the one being developed by NanoViricides. This is in complete contrast with drugs based on 
antibodies, antibody cocktails, as well as with preventative vaccines. 
NanoViricides has been developing broad-spectrum anti-coronavirus drug candidates since the early reports of the new 
virus from China, then known as 2019-nCoV. We were able to bootstrap this development using our knowledge gained in the 
earlier endeavors working on SARS-CoV-1 and MERS coronaviruses. 
NanoViricides has been able to conduct this novel drug development at an accelerated pace because of the benefits of 
its platform technology. We were able to bootstrap our SARS-CoV-2 drug development efforts using the c-GMP-compatible 
manufacturing processes developed for our then flagship NV-HHV-101 drug candidate for shingles dermal treatment. 
Further, NanoViricides has a tremendous advantage in that the Company has its own cGMP-capable manufacturing facility 
in Shelton, CT. This facility is capable of producing approximately 4kg of the COVID-19 drug per batch. We anticipate 
that this scale would be sufficient for human clinical trials, and possibly for initial introduction under 
Compassionate Use, Emergency Use Authorization or similar regulatory approval. 
"We are well poised and are advancing the fight against the coronaviruses with a weapon that has perhaps the best 
characteristics for succeeding in taming this pandemic," said Anil R. Diwan, PhD, President and co-Founder of 
NanoViricides, Inc., and co-Inventor of its platform technologies and drug candidates. 
About NanoViricides 
NanoViricides, Inc. (the "Company")(www.nanoviricides.com) is a development stage company that is creating special 
purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed 
to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its 
first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical 
candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact 
date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants. 
The Company is now working on performing required safety pharmacology studies and completing an IND application. The 
Company believes that since remdesivir already is US FDA approved, our drug candidate encapsulating remdesivir is 
likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed 
our own drug candidates independently. 
The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment 
of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 
program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug 
development work. 
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral 
diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, 
Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are 
based on the TheraCour(R) nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides 
holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms 
in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), 
Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster 
Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola 
/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license 
for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and 
has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field 
licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on 
licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established 
at its foundation in 2005. 
As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical 
product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, 
there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient 
effectiveness and safety for human clinical development. Further, there can be no assurance at this time that 
successful results against coronavirus in our lab will lead to successful clinical trials or a successful 
pharmaceutical product. 
This press release contains forward-looking statements that reflect the Company's current expectation regarding future 
events. Actual events could differ materially and substantially from those projected herein and depend on a number of 
factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 
"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the 
Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve 
known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and 
which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The 
Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to 
update the reasons actual results could differ materially from those anticipated in these forward-looking statements, 
even if new information becomes available in the future. Important factors that could cause actual results to differ 
materially from the company's expectations include, but are not limited to, those factors that are disclosed under the 
heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States 
Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify 
all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a 
nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain 
regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our 
product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND 
application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

(MORE TO FOLLOW) Dow Jones Newswires

January 27, 2021 06:15 ET (11:15 GMT)